Trial Design: Studies using common standard outcome measures (Milestone 10.C)
Achieved
Timeline Start - End
2015 - 2020Research Implementation Area
Trial DesignInitiate 3-4 clinical research studies using common standard outcome measures.
Success Criteria
- Data comparisons conducted from clinical studies using common standard outcome measures.
Summary of Key Accomplishments
Three secondary prevention trials supported by NIA (A4, API, DIAN-TU) are using several common outcome measures such as CDR (clinical dementia rating), WMS (Wechsler Memory Scale), amyloid and tau PET, CSF amyloid, and others. In addition, the NIA supported natural history studies (ADNI, DIAN, ABC-DS, HABS-HD and LEADS) are using several common outcome measures enabling data comparisons across multi-ethnic populations and different types of early and late onset AD.
The key accomplishments summary is current as of March 2022.
Accomplishments/Implementation Activities
Research Programs and Resources
- Alzheimer’s Prevention Initiative (API)
- Anti-Amyloid Treatment In Asymptomatic Alzheimer’s Disease Study (A4 study)
- Dominantly Inherited Alzheimer's Network Trials Unit - Adaptive Prevention Trial (DIAN-TU)
- Collaboration for Alzheimer’s Prevention (CAP): Prevention Trials